13th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium

The 13th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium is presented by Duke Health in collaboration with the UNC School of Medicine and the Pulmonary Hypertension Association.

Date: Friday, November 5, 2021

Time:/Format: 12:00-4:20pm; virtual via Zoom.

 

Download the Agenda 

Register for the event 


Joint Accreditation Statement 

This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development for the advancement of patient care. In support of improving patient care, the Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 3.5 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 3.5 ACPE credit hours. Universal Activity Number:JA0000655-0000-21-273-L04-P

Course Overview: 

This is a one-day symposium with a focus on fortifying the knowledge base of physicians and other allied health professionals involved in diagnosing and treating Pulmonary Arterial Hypertension, keeping them abreast of the ever-changing diagnostic and treatment paradigms. The symposium will address issues as it relates to appropriate diagnostic procedures, proper treatment choices, and timing of referral for more advanced care to pulmonary hypertension centers for healthcare providers at the front lines of screening for and diagnosing Pulmonary Arterial Hypertension (PAH).

The field of pulmonary arterial hypertension is a rapidly developing one, with multiple new treatments introduced in the last 25 years.  This has created a steep learning curve for pulmonologists and cardiologists treating this disease, as well as primary care physicians who must remain mindful to consider the diagnosis in their patients.  We seek to enhance the knowledge base of these physicians keeping them up to date on the evolving body of knowledge on pulmonary vascular disease.  This dynamic state of the field serves to perpetuate a gap in regard to the knowledge of appropriate diagnostic procedures, proper treatment choices, and timing in advancement of care to pulmonary hypertension specialty centers.  It is imperative that those treating this specialized disease have a thoroughly grounded knowledge of the appropriate work up, treatment, and care of the PAH patient. 

The ACCP, AHA, ERS/ESC and WHO have convened on multiple occasions to develop consensus guidelines for the diagnosis and treatment of PAH.  These guidelines have been published in prominent medical journals and presented at national meetings, thus exposing thousands of practitioners to these standardized approaches and promoting appropriate, structured care paradigms. The 13th annual RTP PH symposium will reinforce the current diagnostic and management guidelines of PAH put forth by the 6th World Symposium on Pulmonary Hypertension in 2018, as well as updates from subsequent national and international conferences. We will also explore newer things on the immediate horizon. There will be a focus on new pathways for treatment including BMPR2 and TGF beta signaling that are actively being investigated, newer methods of assessing functional status of our patients including actigraphy. We will discuss updated methods to better diagnose and discern true PAH Group affiliation as many are seeing more complicated patients with perhaps multiple etiologies. We will provide some interactive cases as well as standard lecture and discussion to emphasize this. We will discuss care of the PAH patient that is critically ill and use cases to enhance decision making for challenging and nuanced presentations of PH.  It will provide a plentiful forum for questions and discussion, providing reinforcement of appropriate care practices and availability of regional referral centers. In addition, there will be cased based interactive session based, focusing on diagnostic imaging specific to these cases to showcase specific techniques that are useful in the diagnosis and treatment of this population.

Course Directors:

H. James Ford, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Terry Fortin, MD
Associate Professor of Medicine
Co-Director, Pulmonary Vascular Disease Center
Division of Cardiology
Duke University Medical Center 

Invited Speakers:

Mazen Al-Qadi, MD
Assistant Professor of Medicine
Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Talal Dahhan, MD
Assistant Professor of Medicine
Division of Pulmonary, Allergy, and Critical Care Medicine
Duke University Medical Center 

Richard Krasuski, MD
Professor of Medicine
Division of Cardiology
Duke University Medical Center

Barbara LeVarge, MD
Assistant Professor of Medicine
Associate Director, Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Professor Nick Morrell
BHF Professor of Cardiopulmonary Medicine
Research Director, National Pulmonary Hypertension Service,
Papworth Hospital
University of Cambridge

Kishan Parikh, MD
Assistant Professor of Medicine
Division of Cardiology
Duke University Medical Center

Ioana Preston, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension Center
Pulmonary Function Lab Director
Tufts University School of Medicine

Sudarshan Rajagopal, MD, PhD
Associate Professor of Medicine
Co-Director, Duke Pulmonary Vascular Disease Center
Division of Cardiology
Duke University Medical Center

Lisa Rose-Jones, MD
Associate Professor of Medicine, Division of Cardiology
Program Director, Cardiovascular Disease Fellowship Program
University of North Carolina at Chapel Hill

Ryan Tedford, MD
Dr. Peter C. Gazes Endowed Chair in Heart Failure
Professor of Medicine/Cardiology
Section Chief, Heart Failure
Medical Director, Cardiac Transplantation
Director, Advanced Heart Failure & Transplant Fellowship Training Program
Medical University of South Carolina (MUSC)

Jordan Whitson, MD
Assistant Professor of Medicine
Division of Pulmonary, Allergy and Critical Care Medicine
Duke University Medical Center

Target Audience:

This program is designed to meet the continuing education (CE) needs of pulmonologists, cardiologists, nurses, pharmacists, and other allied healthcare professionals involved in the treatment of pulmonary hypertension.

Learning Objectives:

  • Describe classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6th World Symposium, as well as the treatment options with respect to PAH-specific therapies.
  • Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy.
  • Explain the thought processes and unique therapies that are specific to this population.
  • Identify diagnostics used in the evaluation of pulmonary hypertension and CTEPH. Focused attention on echocardiography, CT scan, VQ scan, PA grams and CTA, cMRI, and right heart catheterization hemodynamic profiles.
  • Describe principles and procedures of right heart cath that will help optimally characterize the disease process beyond basic measures as we find an increasing population undergoing evaluation of pulmonary hypertension.
  • Discuss the role of activity in patients with PAH and how we can better assess functional status with actigraphy as a new metric both for research and clinical practice. This is perhaps more relevant in the new age of virtual visits.
  • Recognize the scientific background in BMPR2 and TGF- Beta signaling as current investigational pathways for therapeutic application.

Registration for the virtual afternoon symposium (12:00-4:20pm) is complimentary, but required. 

Register for the event 


Cancellation Policy

All cancellation requests must be submitted in writing to Christy Darnell via email (christy.darnell@duke.edu). 

After The Event

To complete all course requirements and claim continuing education credits, please do the following:

  • Receive email from Duke CME office next week with link to the course evaluation. 
  • Complete the course evaluation.
  • Attest to your hours of completion.
  • Download your certificate.